Cartesian Therapeutics (RNAC) Tops Q3 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Join SI Premium – FREE
Cartesian Therapeutics (NASDAQ: RNAC) reported Q3 EPS of ($0.38), $0.63 better than the analyst estimate of ($1.01).
For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tapestry (TPR) Tops Q1 EPS by 26c; offers guidance
- Unity Software Inc. (U) Tops Q3 EPS by 41c, Offers Guidance
- BlackSky (BKSY) Tops Q3 EPS by 32c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
